Suchergebnisse - "Asselah, Tarik"

PubPharm (26)

1

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1) : a multicentre, double-blind, active-controlled, randomised, phase 2b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Yuen, M. | Asselah, T. | Jacobson, I. | +116

CommentIn: Lancet Gastroenterol Hepatol. 2023 Sep;8(9):772-773. - PMID 37442151

2

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

enthalten in: Gut | 2023

von Janssen, H. | Hou, J. | Asselah, T. | +16

3

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

enthalten in: The New England journal of medicine | 2022

von Yuen, M. | Lim, S. | Plesniak, R. | +132

CommentIn: N Engl J Med. 2022 Nov 24;387(21):1996-1998. - PMID 36346068

4

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection : A randomized study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Asselah, T. | Pol, S. | Hezode, C. | +21

5

Obeticholic acid for the treatment of non-alcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Younossi, Z. | Ratziu, V. | Loomba, R. | +133

CommentIn: Lancet. 2019 Dec 14;394(10215):2131-2133. - PMID 31813639

6

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2018

von Asselah, T. | Kowdley, K. | Zadeikis, N. | +19

7

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

enthalten in: The New England journal of medicine | 2018

von Zeuzem, S. | Foster, G. | Wang, S. | +35

8

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection : 2 Phase 3 Randomized Trials

enthalten in: Gastroenterology | 2017

von Jacobson, I. | Lawitz, E. | Gane, E. | +27

9

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

enthalten in: The New England journal of medicine | 2017

von Bourlière, M. | Gordon, S. | Flamm, S. | +127

10

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I) : a multicentre, phase 3, randomised open-label trial

enthalten in: The lancet. Gastroenterology & hepatology | 2016

von Asselah, T. | Hézode, C. | Qaqish, R. | +11

CommentIn: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):3-4. - PMID 28404109